Recall of All Doses of Parathyroid Hormone Natpara Issued
Abrupt interruption or discontinuation of Natpara can result in severe hypocalcemia.
Hypoparathyroidism
Case Study: Tingling and Numbness After Thyroid Cancer Surgery
A woman who underwent total thyroidectomy with neck dissection experiences headaches, muscle spasms, and cramps.
Hypoparathyroidism Associated With Chronic Health Conditions, Increased Mortality
Patients with hypoparathyroidism have increased risk for several health conditions including cataracts, epilepsy, cardiovascular disease, cerebrovascular disease, infection, mental illness, and renal failure.
Parathyroid Hormone for Hypoparathyroidism May Be Effective Over Long Term
PTH (1-84) for 7 years is linked to reduced calcium and calcitriol supplementation.
Natpara Injection Now Available in the U.S.
Shire announced the launch of Natpara (parathyroid hormone) for injection indicated as adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism
Natpara Earns FDA Approval for Hypoparathyroidism
The FDA has approved Natpara (parathyroid hormone) to control hypocalcemia in patients with hypoparathyroidism.
Advisory Panel Favors Approval of Natpara
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted to recommend approval of recombinant human parathyroid hormone for hypoparathyroidism.
Recombinant Human Parathyroid Hormone Effective for Hypoparathyroidism
Patients with hypoparathyroidism may benefit from treatment with recombinant human parathyroid hormone.
Next post in Bone Metabolism
